Table 3.

Median survival outcomes of patients with stage III NSCLC on the basis of treatment modality and nodal response after neoadjuvant CRT^a

	Our Analysis	Intergroup 0139	RTOG 0229	RTOG 0617
Trimodality
All patients	59.9	23.6	-	-
Lobectomies only	61.0	33.6	-	-
pN0	60.2	34.4	MST not reachedc	-
pN1-N3	35.7	26.4	32.7	-
No Surgery	20.1	7.9	7.5	-
Planned Bimodality
All patients	17.3	22.2	-	-
Lobectomies only	-	21.7b	-	-
60 Gy	-	-	-	28.7
74 Gy	-	-	-	20.3
P-values
	< .001e	.002,d < .001e	.0002	.004

CRT, chemoradiation therapy; MST, median survival time; NSCLC, non-small cell lung cancer; RTOG, radiation therapy oncology group.

^aEstimated median survival in months.

^bUnplanned exploratory matched analysis for this group.

^cMedian survival time (MST) not reached.

^dWhen comparing lobectomy patients to bimodality.

^eWhen comparing pN0 to pN1-N3 and no surgery.